ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma is listed on Nasdaq Stockholm main market (small cap) under the ticker ACE

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• 2019-03-21Stabilisation notice
• 2019-03-12Trading in Ascelia Pharma’s shares on Nasdaq Stockholm commences tomorrow
• 2019-03-06Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed